Swiss Medical Device Legal Architecture: How TPA, MedDO and IvDO Divide the Work

This article is number 01 in Volume 1, Regulatory Framework and Fundamentals, of the fifty-part series on medical device registration in Switzerland. Together with the other nine articles in this volume it forms a complete deliverable on this topic. The publication timestamp, article number, article title and unique URL are listed in the table below.

1. Key takeaways

Switzerland has no single unified medical device code. The legal layer is the Therapeutic Products Act (TPA, SR 812.21); the ordinance layer consists of the Medical Devices Ordinance (MedDO, SR 812.213) and the Ordinance on In Vitro Diagnostic Medical Devices (IvDO, SR 812.219); and the technical requirements layer is reached through citation clauses in MedDO and IvDO that point to the annexes of the EU MDR and IVDR. The correct order for any compliance search is TPA first, then MedDO or IvDO, then the cited EU annexes. Citing an EU MDR article directly and claiming Swiss compliance on that basis alone does not hold procedurally, because Swiss obligations exist only where the Swiss ordinances actually incorporate the EU text.

2. Legal basis

Verification entry points: the current official texts of SR 812.21, SR 812.213 and SR 812.219 on the federal compilation of legislation Fedlex (fedlex.admin.ch), together with the medical devices topic pages published by Swissmedic. These two sources together cover every layer of the architecture described in this article and should be the first stop whenever a citation needs to be confirmed against the version actually in force on a given date.

3. Expert insights

1. The three tiers stand in a relationship of authorisation, not substitution. The TPA only allocates duties and powers: it establishes official market surveillance (Art. 58) and notification obligations (Art. 59), and it delegates the technical bar to ordinances issued by the Federal Council. MedDO and IvDO in turn outsource annex-level technical requirements to the EU texts. The cost of this design is that companies must maintain indexes into two bodies of law; the benefit is that Switzerland can follow EU technical updates without rebuilding its own framework. The counterweight is that when the EU text is revised but MedDO has not synchronised its citation, the version applicable in Switzerland remains the one in force at the time of citation, and an EU compliance package cannot simply be transplanted unchanged.
2. Separate legislation for IVDs creates a timeline that can move independently. IvDO was amended on 20 November 2024 (AS 2024 742) to introduce a device registration obligation, effective from 1 January 2025, and this change did not touch MedDO at all. Companies that hold both device and IVD product lines must manage the two timelines separately; scheduling production purely to the MedDO rhythm will cause IVD milestones to be missed. Treat the two ordinances as two clocks that tick at different speeds, and plan registrations, vigilance staffing and budget cycles accordingly.
3. The version of a provision matters more than its number. The latest version of MedDO is valid from 1 July 2026, and the supporting documents for the same Art. 15 differ between versions. Citing a provision without stating the version date effectively transfers the verification burden to the reviewer, and it invites challenges during audits. Every internal SOP, registration dossier and submission cover letter should therefore carry the version date of the ordinance on which it relies, so that any reader can reconstruct the legal basis without searching the compilation again.

4. Practical recommendations

1. Build a three-tier cross-reference table: TPA authorising provisions on one side, MedDO and IvDO obligation provisions in the middle, and the cited EU annexes on the other, with the version date marked on every entry.
2. Write internal documents uniformly as MedDO Art. X with the version date in brackets, and prohibit citing MDR Art. X alone as a Swiss compliance basis.
3. Classify combination products before assigning their legal source: devices containing an IVD component require a simultaneous check of MedDO Art. 1(3) and the IvDO.
4. Put the three version milestones of 1 November 2023, 1 January 2025 and 1 July 2026 into the regulatory watch list and assign owners for each.
5. Track TPA Art. 47c (supply chain disclosure) and Art. 55/56 (integrity and transparency) as a separate post-market compliance line, kept apart from the technical requirements workstream so that neither blocks the other.

5. Verification checklist

• □ It has been confirmed whether the product falls within the scope of MedDO or IvDO, and the exceptions under Art. 2 have been ruled out
• □ Every MedDO/IvDO provision cited carries the date of the version from which it is taken
• □ Every cited EU annex is supported by an explicit citation provision in MedDO/IvDO
• □ For combination products, the applicability of MedDO Art. 1(3) and of the IvDO has been checked separately
• □ The regulatory watch list covers the version switch of 1 July 2026
• □ TPA-level supply chain disclosure and integrity and transparency duties have been assigned to responsible departments

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers and economic operators entering the Swiss market with end-to-end Swissmedic registration and compliance services, including ordinance mapping under TPA, MedDO and IvDO, CHRN and swissdamed registration, CH-REP arrangements, classification and technical documentation review, and regulatory watch across version changes. Our team turns the three-tier architecture described above into an actionable project plan with owners, deadlines and evidence trails. For tailored guidance on your product portfolio, contact info@grzanglobal.com.